沙眼衣原体疫苗与淋病奈瑟球菌疫苗的研究进展  

Development of vaccines against Chlamydia trachomatis and Neisseria gonorrhoeae

作　　者：李雅梅 修乐山 彭俊平[1] Li Yamei;Xiu Leshan;Peng Junping(National Health Commission Key Laboratory of Systems Biology of Pathogens,Institute of Pathogen Biology,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100176,China)

机构地区：[1]中国医学科学院/北京协和医学院病原生物学研究所,国家卫生健康委病原系统生物学重点实验室,北京100176

出　　处：《国际流行病学传染病学杂志》2020年第5期439-443,共5页International Journal of Epidemiology and Infectious Disease

基　　金：中国医学科学院医学与健康创新工程协同创新团队项目(2016-I2M-3-021)。

摘　　要：沙眼衣原体(Chlamydia trachomatis,CT)感染和淋病奈瑟球菌(Neisseria gonorrhoeae,NG)感染是常见的性传播疾病,目前尚未有针对它们的有效疫苗问世,但疫苗相关研究均取得了较大进展。CT疫苗CTH522已经通过Ⅰ期临床试验,有望填补CT疫苗的空白。同时,多种有效NG候选疫苗靶标抗原也被开发,给疫苗研发工作带来了很大的希望。本文对CT和NG疫苗研发工作中的进展、障碍和临床实验进行综述,旨在为后续的疫苗开发提供参考。Chlamydia trachomatis(CT)and Neisseria gonorrhoeae(NG)infections are the most common sexually transmitted infections.Although effective vaccines against these two pathogens have not yet been launched,great progress has been made in research and development of the vaccines.For chlamydia vaccine,candidate CTH522 has passed the phaseⅠclinical trial,which is expected to fill the blank in chlamydia vaccine.For gonococcal vaccine,a variety of effective vaccine candidates have been developed,which bring great hope to vaccine development.In this article,the progress,obstacles and clinical trials in chlamydia and gonococcal vaccine development are reviewed,so as to provide reference for subsequent vaccine study.

关 键 词：衣原体 沙眼 淋球菌 蛋白质疫苗 DNA疫苗 临床试验 

分 类 号：R392-3[医药卫生—免疫学]